Global Trends in Monoclonal Antibodies Industry Highlighted with Competitive, Technological and R&D Landscape

Market Research HUB

Albany, US, 2017-Nov-14 — /EPR Network/ —  Antibodies are increasingly becoming the preferred choice to treat several disorders such as respiratory diseases, oncology, and autoimmune diseases. Many of these antibodies are being approved for diseases like inflammation and cancer. At present, monoclonal antibodies are widely used for the treatment of various types of cancers. A lot of research is conducting to create monoclonal antibodies that are able to cure various diseases. Rising incidence of cancer and other chronic diseases is engendering the high demand for biologics, which is serving as the key contributing factor for the growth of monoclonal antibodies industry. To provide comprehensive view of the global market, a study titled “Monoclonal Antibodies– Global Trends in the Competitive, Technological and R&D Landscape” has been broadcasted to the wide repository of Market Research Hub (MRH). This study provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of mAbs, and assesses key developments in manufacturing and development, covering strategies to combat challenges associated with the use of mAbs in human patients.

Request Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1362755

Apart from the above elements, the readers will be able to understand the current status of the field of therapeutic monoclonal antibodies, and the relative clinical and commercial success of currently marketed products. It has been analyzed that a substantial number of mAb products have entered the market in the recent past. However, the majority are still in early-stage development, indicating delays and setbacks in the progression of potential products. Current facts and figures reveal that the pipeline is highly active, with 2,836 mAbs currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. Additionally, there are currently 85 mAb programs in Phase III development, and 22 at the Pre-registration stage, accounting for just under 4% of the total mAb pipeline.

Monoclonal antibodies can be defined as, a collection of antibodies produced from a single B-cell clone. These antibodies, therefore, share binding specificity towards a certain antigen and can be used as a means of targeted therapy within a number of indications across the pharmaceutical market. Also, growing awareness levels amongst patients and physicians pertaining to the applications of mAb therapy are contributing toward further growth in the market. The report further also stated that mAbs are the largest and fastest-growing segment of the biopharmaceutical sector, and account for almost half of the global revenue accrued from this area annually.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/monoclonal-antibodies-global-trends-in-the-competitive-technological-and-rd-landscape-report.html

Additionally, a granular assessment of the pipeline is provided across the four most active therapy areas for mAbs: oncology, infectious diseases, immunology and central nervous system disorders. For each of these, the study assesses the pipeline for mAbs split by therapy area, mAb type, and stage of development. Key marketed products included in the study are Remicade, Lucentis, Rituxan, Avastin, Herceptin, Opdivo, Humira, Stelara and Soliris.

Moreover, the report provides a detailed assessment of the prevailing vendor landscape. It also profiles the leading players operating in the market and leveraging industry-leading analytical tools, gauges the threats and opportunities that these companies may face over the course of the forecast period between 2016 and 2024.

Enquire About this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1362755

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: – 800-998-4852 (US-Canada)
Email:- press@marketresearchhub.com
Website:- https://www.marketresearchhub.com/
Read Industry News at :- https://www.industrynewsanalysis.com/